Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

Nat Med. 1995 Dec;1(12):1297-302. doi: 10.1038/nm1295-1297.


Dendritic cells, the most potent 'professional' antigen-presenting cells, hold promise for improving the immunotherapy of cancer. In three different well-characterized tumour models, naive mice injected with bone marrow-derived dendritic cells prepulsed with tumour-associated peptides previously characterized as being recognized by class I major histocompatibility complex-restricted cytotoxic T lymphocytes, developed a specific T-lymphocyte response and were protected against a subsequent lethal tumour challenge. Moreover, in the C3 sarcoma and the 3LL lung carcinoma murine models, treatment of animals bearing established macroscopic tumours (up to 1 cm2 in size) with tumour peptide-pulsed dendritic cells resulted in sustained tumour regression and tumour-free status in more than 80% of cases. These results support the clinical use of tumour peptide-pulsed dendritic cells as components in developing effective cancer vaccines and therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antigen Presentation
  • Bone Marrow Cells*
  • Dendritic Cells / immunology
  • Dendritic Cells / transplantation*
  • Disease Models, Animal
  • Female
  • Humans
  • Lung Neoplasms / therapy*
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Proteins / immunology
  • Sarcoma, Experimental / therapy*
  • T-Lymphocytes, Cytotoxic / metabolism
  • Tumor Cells, Cultured
  • Vaccines, Synthetic / immunology*


  • Neoplasm Proteins
  • Vaccines, Synthetic